Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial

The article fragment says three major pharma and vaccine companies are trading against their headlines and lists Moderna at $231. It provides no further context, time period, or market move, so the significance cannot be assessed.